Advertisement
Grab your lab coat. Let's get started
Welcome!
Welcome!
Create an account below to get 6 C&EN articles per month, receive newsletters and more - all free.
It seems this is your first time logging in online. Please enter the following information to continue.
As an ACS member you automatically get access to this site. All we need is few more details to create your reading experience.
Not you? Sign in with a different account.
Not you? Sign in with a different account.
ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Pharmaceuticals
BMS, Ambrx Partner On Biotherapies
by Rick Mullin
October 3, 2011
| A version of this story appeared in
Volume 89, Issue 40
Bristol-Myers Squibb is acquiring worldwide rights to research, develop, and commercialize biologics based on Ambrx’ Fibroblast Growth Factor 21 (FGF-21) protein, a potential treatment for type 2 diabetes, and the hormone relaxin for potential use in treating heart failure. BMS will pay Ambrx $24 million up front and may make milestone and royalty payments. FGF-21 is in late-stage preclinical studies. Relaxin is a naturally occurring hormone known for its role in pregnancy and childbirth. It has been shown in preclinical studies to improve cardiac function.
The power is now in your (nitrile gloved) hands
Sign up for a free account to get more articles. Or choose the ACS option that’s right for you.
Already have an ACS ID? Log in
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on Twitter